$4.73
1.94% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US92764N1028
Symbol
VIR

Vir Biotechnology Inc Stock price

$4.73
-0.88 15.69% 1M
-2.01 29.82% 6M
-2.61 35.56% YTD
-4.96 51.19% 1Y
-19.63 80.58% 3Y
-35.18 88.15% 5Y
+1.04 28.18% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.09 1.94%
ISIN
US92764N1028
Symbol
VIR
Sector
Industry

Key metrics

Market capitalization $653.87m
Enterprise Value $-139.84m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.33
EV/Sales (TTM) EV/Sales -6.70
P/S ratio (TTM) P/S ratio 31.35
P/B ratio (TTM) P/B ratio 0.63
Revenue growth (TTM) Revenue growth -73.79%
Revenue (TTM) Revenue $20.86m
EBIT (operating result TTM) EBIT $-583.47m
Free Cash Flow (TTM) Free Cash Flow $-422.14m
Cash position $889.81m
EPS (TTM) EPS $-4.22
P/E forward negative
P/S forward 38.65
EV/Sales forward negative
Short interest 12.08%
Show more

Is Vir Biotechnology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Vir Biotechnology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Vir Biotechnology Inc forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Vir Biotechnology Inc forecast:

Buy
78%
Hold
22%

Financial data from Vir Biotechnology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
21 21
74% 74%
100%
- Direct Costs 14 14
41% 41%
66%
7.17 7.17
87% 87%
34%
- Selling and Administrative Expenses 94 94
32% 32%
449%
- Research and Development Expense 484 484
2% 2%
2,320%
-571 -571
1% 1%
-2,735%
- Depreciation and Amortization 13 13
42% 42%
62%
EBIT (Operating Income) EBIT -583 -583
2% 2%
-2,797%
Net Profit -578 -578
7% 7%
-2,769%

In millions USD.

Don't miss a Thing! We will send you all news about Vir Biotechnology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vir Biotechnology Inc Stock News

Neutral
Business Wire
about 8 hours ago
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, and Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head, Oncology, will participate in a virtual fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit on Tuesday, May 27 at 1:30 p.m. PT / 4:30 p.m. ET. ...
Neutral
Business Wire
8 days ago
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14 at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada. A live webcast of the fireside chat will be made available under Event...
Neutral
Business Wire
12 days ago
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced 24-week post-end of treatment data from Part B of the ongoing MARCH Phase 2 clinical study evaluating tobevibart and elebsiran without or with pegylated interferon alpha (PEG-IFNα) in participants with chronic hepatitis B (CHB). The study-defined primary endpoint, proportion of participants with undetectable h...
More Vir Biotechnology Inc News

Company Profile

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Head office United States
CEO Marianne Backer
Employees 408
Founded 2016
Website www.vir.bio

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today